The Role of Epigenetics in Pancreatic Ductal Adenocarcinoma

Roalsø, Marcus; Hald, Øyvind Holsbø; Ansari, Daniel; Andersson, Roland; Søreide, Kjetil

doi:10.1007/978-3-030-53786-9_22

Cited by 2 publications

(15 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar drug-related adverse events were found in a phase II trial of the dual Polo-like kinase/BRD4 bromodomain BET inhibitor BI 2536 in chemo-näive unresectable PDAC patients [100]. [14] and reproduced with permission from Springer © 2021.…”

Section: Epigenetic Therapeutic Optionsmentioning

confidence: 57%

See 1 more Smart Citation

Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma

Roalsø

Hald

Alexeeva

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with limited treatment options. Emerging evidence shows that epigenetic alterations are present in PDAC. The changes are potentially reversible and therefore promising therapeutic targets. Epigenetic aberrations also influence the tumor microenvironment with the potential to modulate and possibly enhance immune-based treatments. Epigenetic marks can also serve as diagnostic screening tools, as epigenetic changes occur at early stages of the disease. Further, epigenetics can be used in prognostication. The field is evolving, and this review seeks to provide an updated overview of the emerging role of epigenetics in the diagnosis, treatment, and prognostication of PDAC.

show abstract

Section: Epigenetic Therapeutic Optionsmentioning

confidence: 57%

“…Epigenetic alterations appear early during the disease course, making them candidates for potential diagnostic as well as prognostic biomarkers [14]. As PDAC is largely asymptomatic prior to advanced disease, early diagnosis is imperative to improve diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma

Roalsø

Hald

Alexeeva

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Epigenetic regulation and the corresponding changed chromatin states frequently occur in genes partaking in oncogenic signaling, metabolic alterations, and the metastatic process. [9,[20][21][22][23][24][25][26]. These changes influence tumor development and progression by activating oncogenes and shutting down tumor suppressor genes.…”

Section: Genetics and Epigenetics In Pancreatic Cancermentioning

confidence: 99%

“…In contrast, it emerges as a late oncogenic driver after epigenetic changes have been created by founder mutations in other malignancies [3]. Other genetic mutations driving PDAC are the inactivation of the tumor suppressors TP53 and CDKN2A, and attempts at targeting therapy against these mutations have proved futile [9]. Considering these, it goes without saying that to improve the prognosis of PDAC, we need early diagnostic biomarkers and other modalities of treatment that target epigenetic alterations.…”

Section: Introductionmentioning

confidence: 99%

“…This contrasts with Pancreatic Neuroendocrine Tumors (PNET), which mostly run an indolent course [ 8 ]. However, it can be argued that PDAC initially runs an indolent course as well, as PDAC is largely asymptomatic before advanced disease, contributing to its high mortality rate [ 9 ] . Other factors contributing to the high mortality of PDAC include the absence of biomarkers for early disease detection and the complexity of tumor biology and genomics, limiting the effectiveness of conventional medical therapy [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Markers of Pancreatic Cancer: A 10-Year Retrospective Review of Molecular Advances

Jacks¹,

Ekpemiro²,

Adeosun³

et al. 2022

Cureus

View full text Add to dashboard Cite

Pancreatic cancer remains the third leading cause of death amongst men and women in the United States. Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer maintains its reputation of being the most aggressive with a poor prognosis. One of the contributing factors to the high mortality of PDAC is the absence of biomarkers for early detection of disease and the complexity of tumor biology and genomics. In this review, we explored the current understanding of epigenetics and diagnostic biomarkers in PDAC and summarized recent advances in molecular biology. We discussed current guidelines on diagnosis, prognosis, and treatment, especially in high-risk individuals. We also reviewed studies that have touched on identifying biomarkers and the role they play in making early diagnosis although there are currently no screening tools for PDAC. We explored the recent understanding of epigenetic alterations of PDAC and the future implications for early detection and prognosis. In conclusion, the new and emerging advances in the detection and treatment of PDAC can lead to an improvement in the current outcome of PDAC.

show abstract

The Role of Epigenetics in Pancreatic Ductal Adenocarcinoma

Cited by 2 publications

References 65 publications

Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma

Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma

Molecular Markers of Pancreatic Cancer: A 10-Year Retrospective Review of Molecular Advances

Contact Info

Product

Resources

About